[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336629-105":59,"doc-detail-336629-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","treatment-outcome-according-to-genetic-tumour-alterations-and-clinical-characteristics-in-digestive-high-grade-neuroendocrine-neoplasms-clinical-studies","Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms - Clinical Studies","","Advanced digestive high-grade neuroendocrine neoplasms (HG-NEN) show limited chemotherapy efficacy and poor prognosis, with few predictive or prognostic markers for palliative cis/carboplatin plus etoposide. A prospective cohort of digestive HG-NEN patients (n=229) was molecularly profiled by sequencing tumour DNA across 360 genes and linked with clinical data. Results identify TP53 and RB1 patterns influencing response or immediate progression in NEC, while ATRX, ARID1A, and ERS1 relate to shorter PFS in NET G3.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/treatment-outcome-according-to-genetic-tumour-alterations-and-clinical-characteristics-in-digestive-high-grade-neuroendocrine-neoplasms-clinical-studies/336629/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/treatment-outcome-according-to-genetic-tumour-alterations-and-clinical-characteristics-in-digestive-high-grade-neuroendocrine-neoplasms-clinical-studies/336629.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main aim of the study?","Question",{"text":112,"@type":113},"To identify genetic alterations that predict first-line chemotherapy efficacy and survival in digestive high-grade neuroendocrine neoplasms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients and tumours profiled in this research?",{"text":117,"@type":113},"Digestive HG-NEN patients (n=229) were prospectively included, with tumour DNA sequenced across 360 cancer-related genes to assess mutations and copy number alterations, then linked to clinical outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which genetic alterations were linked to chemotherapy response or progression in neuroendocrine carcinoma (NEC)?",{"text":121,"@type":113},"In cis/carboplatin and etoposide (PE)-treated NEC, TP53 mutation predicted an inferior response rate overall; no BRAF mutation was associated with response. In small-cell NEC, TP53 mutation related to longer overall survival, while RB1 deletions predicted lack of immediate progression. In non-small cell NEC, APC mutation was associated with immediate progression and shorter PFS.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336629,1790701937,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/bjc](www.nature.com/bjc British)[ British](www.nature.com/bjc British) Journal of Cancer  \nARTICLE OPEN   \nClinical Studies  \nTreatment outcome according to genetic tumour alterationsand clinical characteristics in digestive high-grade neuroendocrine neoplasms  \nHege Elvebakken 1,2 ✉, Andreas Venizelos3, Aurel Perren 4, Anne Couvelard5, Inger Marie B. Lothe6, Geir O. Hjortland7, Tor Å . Myklebust 8,9, Johanna Svensson10, Herish Garresori11, Christian Kersten 12, Eva Hofsli1,13, Sönke Detlefsen 14,15, Lene W. Vestermark16, Stian Knappskog 3,17,19 and Halfdan Sorbye17,18,19  \n© The Author(s) 2024  \n\n|  | BACKGROUND: Chemotherapy has limited efﬁcacy in advanced digestive high-grade neuroendocrine neoplasms (HG-NEN) and prognosis is dismal. Predictive markers for palliative chemotherapy are lacking, and prognostic markers are limited.\u003Cbr>METHODS: Digestive HG-NEN patients (n = 229) were prospectively included 2013–2017 . Pathological re-assessment revealed 188 neuroendocrine carcinomas (NEC) and 41 neuroendocrine tumours (NET G3) . Tumour-DNA was sequenced across 360 cancerrelated genes, assessing mutations (mut) and copy number alterations. We linked sequencing results to clinical information and explored potential markers for ﬁrst-line chemotherapy efﬁcacy and survival.\u003Cbr>RESULTS: In NEC given cis/carboplatin and etoposide (PE), TP53mut predicted inferior response rate in multivariate analyses (p = 0.009) and no BRAFmut NEC showed response. In overall assessment of PE-treated NEC, no genetic alterations were prognostic for OS. For small-cell NEC, TP53mut were associated with longer OS (p = 0.011) and RB1 deletions predicted lack of immediateprogression (p = 0.003) . In non-small cell NEC, APC mut were associated with immediate-progression and shorter PFS (p = 0.008/ p = 0.004) . For NET G3, ATRXmut, ARID1A- and ERS1 deletions were associated with shorter PFS.\u003Cbr>CONCLUSION: Correlations between genetic alterations and response/immediate-progression to PE were frequent in NEC but affected PFS or OS only when subdividing for cell-type The classiﬁcation of digestive NEC into large-and small-cell seems therefore |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| .\u003Cbr>molecularly and clinically relevant. |  |  |\n|  | British Journal of Cancer (2024) 131:676–684; [https://doi.org/10.1038/s41416-024-02773-w](https://doi.org/10.1038/s41416-024-02773-w) |  |\n|  |  |  |\n\nINTRODUCTION  \nNeuroendocrine neoplasms (NEN) encompass a variety of neoplasms with different phenotypes, ranging from indolent low-grade neuroendocrine tumours (NET) to aggressive neuroendocrine carcinoma (NEC) . The 2019 WHO classiﬁcation of digestive high-grade NEN (HG-NEN) separated well-differentiated NET G3 from poorly differentiated NEC, both with a high proliferation deﬁned by Ki-67 > 20%[1] . Digestive NET G3 and NEC entities differ in clinical and molecular characteristics, response to treatment and prognosis [2–5] . Metastatic NEC is associated with  \nan especially poor prognosis, with median overall survival ranging from 1 month if untreated, to 11–12 months if given chemotherapy [6–8] . Established ﬁrst-line palliative chemotherapy consisting of cis/carboplatin and etoposide is extrapolated from treatment of small-cell lung cancer (SCLC) based on clinical and morphological similarities [9–11] . The treatment has been unchanged since the 1990s, as has the dismal prognosis. Up to 30% of digestive NEC have an immediate disease progression evident at ﬁrst radiological evaluation after receiving cis/carboplatin and etoposide. Progression free survival (PFS) is only 4–5 months. Metastatic NET  \n1Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. 2Department of Oncology, Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, Norway. 3K.","cbCaifnNwqgDnaeA","https://ap.wps.com/l/cbCaifnNwqgDnaeA","pdf",528718,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What was the main aim of the study?\",\"answer\":\"To identify genetic alterations that predict first-line chemotherapy efficacy and survival in digestive high-grade neuroendocrine neoplasms.\"},{\"question\":\"How were patients and tumours profiled in this research?\",\"answer\":\"Digestive HG-NEN patients (n=229) were prospectively included, with tumour DNA sequenced across 360 cancer-related genes to assess mutations and copy number alterations, then linked to clinical outcomes.\"},{\"question\":\"Which genetic alterations were linked to chemotherapy response or progression in neuroendocrine carcinoma (NEC)?\",\"answer\":\"In cis/carboplatin and etoposide (PE)-treated NEC, TP53 mutation predicted an inferior response rate overall; no BRAF mutation was associated with response. In small-cell NEC, TP53 mutation related to longer overall survival, while RB1 deletions predicted lack of immediate progression. In non-small cell NEC, APC mutation was associated with immediate progression and shorter PFS.\"}]","Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms - Clinical Studies | PDF",1790015935,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d92621c2fff07667dda62167f55bdff2.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d22a0f7f4f69633b4d3e4f3cd9b95972.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23b72430c070a2067789f1d98188ccce.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31e913673f5a6accc6770f5f9e233810.webp",980,1301]